Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FZY04
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,357
Award facts
- Contract value 100% obligated
- $11,357.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $11,357.40 by the Defense Logistics Agency (DLA) on September 22, 2025, for the supply of Nucala 100 mg/ml auto-injector units. The contract utilizes a firm fixed-price structure with an ultimate completion date of September 23, 2025, and does not include a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499,999,999 single-award contract valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide.
The DLA, which operates under the Department of Defense, leverages this IDC to distribute essential medications and medical supplies to military health facilities across the globe. Nucala (mepolizumab), an injectable biologic used in the treatment of severe asthma and other eosinophil-mediated conditions, represents the type of specialized pharmaceutical product that DMS Pharmaceutical Group regularly supplies through this contract vehicle. As a critical supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated consistent capability in delivering branded medications, biologics, and medical consumables to Defense Department healthcare sites, supporting the medical readiness and personnel health requirements of the military healthcare system.
Quick answers
Who was awarded contract SPE2DB25FZY04?
SPE2DB25FZY04 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 22, 2025.
How much is contract SPE2DB25FZY04 worth?
The government has obligated $11,357 on SPE2DB25FZY04.
Is contract SPE2DB25FZY04 an order under another contract?
Yes. SPE2DB25FZY04 is a delivery order under SPE2DB20D9135, an indefinite delivery contract.
Was contract SPE2DB25FZY04 competed?
The extent of competition for SPE2DB25FZY04 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award